Press coverage about DBV Technologies (NASDAQ:DBVT) has trended somewhat positive this week, Accern reports. The research firm rates the sentiment of news coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. DBV Technologies earned a daily sentiment score of 0.24 on Accern’s scale. Accern also assigned media stories about the company an impact score of 45.8142134867239 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
DBV Technologies (DBVT) traded down $0.10 on Friday, reaching $26.29. 88,880 shares of the company traded hands, compared to its average volume of 142,368. DBV Technologies has a 52-week low of $20.58 and a 52-week high of $50.57.
Several analysts have recently issued reports on DBVT shares. BidaskClub cut shares of DBV Technologies from a “sell” rating to a “strong sell” rating in a research note on Wednesday, December 6th. Societe Generale cut shares of DBV Technologies from a “buy” rating to a “sell” rating in a research report on Tuesday, October 24th. Zacks Investment Research raised shares of DBV Technologies from a “hold” rating to a “buy” rating and set a $32.00 price target for the company in a research report on Tuesday, October 24th. JMP Securities assumed coverage on shares of DBV Technologies in a research report on Friday, November 17th. They set an “outperform” rating for the company. Finally, Barclays cut their price objective on shares of DBV Technologies from $58.00 to $30.00 and set an “overweight” rating on the stock in a report on Monday, October 23rd. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and nine have issued a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $49.63.
TRADEMARK VIOLATION NOTICE: “Somewhat Positive Press Coverage Somewhat Unlikely to Impact DBV Technologies (DBVT) Stock Price” was originally published by The Lincolnian Online and is owned by of The Lincolnian Online. If you are reading this article on another website, it was stolen and republished in violation of US & international trademark & copyright legislation. The legal version of this article can be viewed at https://www.thelincolnianonline.com/2018/01/13/dbv-technologies-dbvt-receives-media-impact-score-of-0-24-updated-updated.html.
About DBV Technologies
DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin.
Receive News & Ratings for DBV Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies and related companies with MarketBeat.com's FREE daily email newsletter.